News

• Press Release : 26/03/2007
  reMYNDs Parkinsons disease drug discovery program reaches breakthrough
• Press Release : 26/10/2006
  Galapagos licenses RadarScreen from reMYND
• Preparation of Cyclo-Phen-Type ligands : chelators of metal ions as potential therapeutic agents in the treatment of Neurodegenerative diseases
   Boldron C., Van der Auwera I., Deraeve C., Gornitzka H., Wera S., Pitie M., Van Leuven F. & Meunier B. (2005) Chembiochem in press
• Therapeutic effects of PKC activators in Alzheimer
  Etcheberrigaray R., Tan M., Dewachter I., Kuiperi C., Van der Auwera I., Wera S., Qiao L., Bank S., Nelson T.J., Kozikowski A.P., Van Leuven F. & Alkon D.L. (2004) Proc. Natl. Acad. Sci. USA 101, 11141-11146
• Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast
  Zabrocki P., Pellens K., Vanhelmont T., Vandebroek T., Griffioen G., Wera S., Van Leuven F. & Winderickx J. (2005) FEBS J. 272, 1386-1400
• Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast
  Vandebroek T., Vanhelmont T., Terwel D., Borghgraef P., Lemaire K., Snauwaert J., Wera S., Van Leuven F. & Winderickx J. (2005) Biochemistry 44, 11466-11475
• Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer
  Zurbriggen R., Amacker M., Kammer A.R., Westerfeld N., Borghgraef P., Van Leuven F., Van der Auwera I. & Wera S. (2005) J. Mol. Neurosci. 27, 157-166
• A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer
  Van der Auwera I., Wera S., Van Leuven F. & Henderson S.T. (2005) Nutr. Metab. (Lond) 2, 28